144 related articles for article (PubMed ID: 29146052)
1. Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change.
Hariri N; Roma AA; Hasteh F; Walavalkar V; Fadare O
Ann Diagn Pathol; 2017 Dec; 31():14-19. PubMed ID: 29146052
[TBL] [Abstract][Full Text] [Related]
2. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
5. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India.
Ramteke P; Seenu V; Prashad R; Gupta SD; Iyer V; Deo S; Gogia A; Mathur S
Indian J Cancer; 2016; 53(3):366-371. PubMed ID: 28244460
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
[TBL] [Abstract][Full Text] [Related]
7. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Chatterjee D; Bal A; Das A; Singh G
Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
[TBL] [Abstract][Full Text] [Related]
8. Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens.
Hariri N; Hasteh F; Walavalkar V; Roma AA; Fadare O
Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):1-7. PubMed ID: 28549033
[TBL] [Abstract][Full Text] [Related]
9. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
[TBL] [Abstract][Full Text] [Related]
11. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
12. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration.
Zhou X; Zhang J; Yun H; Shi R; Wang Y; Wang W; Lagercrantz SB; Mu K
Oncotarget; 2015 Nov; 6(34):36894-902. PubMed ID: 26384297
[TBL] [Abstract][Full Text] [Related]
13. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
14. Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications.
Shaaban AM; Provenzano E
Pathobiology; 2022; 89(5):297-308. PubMed ID: 35636403
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
16. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.
Basak Oven Ustaalioglu B; Aker Vardar F; Bilici A; Gurleyik G; Erkol B; Kefeli U; Aliustaoglu M
J BUON; 2014; 19(4):879-86. PubMed ID: 25536590
[TBL] [Abstract][Full Text] [Related]
17. Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies.
Desa DE; Bhanote M; Hill RL; Majeski JB; Buscaglia B; D'Aguiar M; Strawderman R; Hicks DG; Turner BM; Brown EB
J Biomed Opt; 2019 Aug; 24(8):1-9. PubMed ID: 31456385
[TBL] [Abstract][Full Text] [Related]
18. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
[TBL] [Abstract][Full Text] [Related]
19. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
Yang YF; Liao YY; Li LQ; Xie SR; Xie YF; Peng NF
Pathol Res Pract; 2013 Dec; 209(12):797-802. PubMed ID: 24183366
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
